Topics

Business
FDA approves knockoff of Amgen's Neupogen chemo recovery drug
FDA approves knockoff of Amgen's Neupogen chemo recovery drug

Amgen Inc., the Thousand Oaks biotech giant, has for decades sold some of the nation's top-selling drugs with little competition. That ended Friday as the FDA approved a competitor's knockoff version of Amgen's chemotherapy recovery drug, Neupogen, heralding a new era of fierce competition — and lower prices — in the multibillion-dollar biologic drug market. The FDA's decision was the first approval of a so-called biosimilar in the U.S., a move set in motion in 2010 by Affordable Care Act provisions designed to cut the cost of biologics to patients. Biologics, unlike chemical drugs, are made from living cells, blood or tissue. They have until now enjoyed...

Loading